Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.36 |
| ▸ | PPARD | Q03181 | 4/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12113866 | 0.96 | FFAR4 (0.41) | FFAR4NAAATLR9TLR8TLR7 | |
| SCHEMBL1311188 | 0.93 | FFAR4 (0.39) | FFAR4NAAATLR9TLR8TLR7 | |
| SCHEMBL8932793 | 0.92 | GRM2 (0.35) | FFAR4BRD4GRM2GRIN1GRIN2B | |
| SCHEMBL22277198 | 0.88 | SSTR5 (0.37) | FFAR4PPARDFFAR1KDM1AGRM2 | |
| SCHEMBL12113787 | 0.88 | FFAR4 (0.41) | FFAR4NAAATLR9TLR8TLR7 | |
| SCHEMBL1311657 | 0.88 | FFAR4 (0.43) | FFAR4TLR9TLR8TLR7PPARD | |
| SCHEMBL13000851 | 0.88 | NAAA (0.34) | FFAR4NAAATLR9TLR8TLR7 | |
| SCHEMBL8970518 | 0.88 | NAAA (0.34) | FFAR4NAAATLR9TLR8TLR7 | |
| SCHEMBL8969240 | 0.87 | NAAA (0.39) | FFAR4NAAAS1PR1GRIN1GRIN2B | |
| SCHEMBL8932755 | 0.87 | FFAR4 (0.39) | FFAR4PPARDFFAR1KDM1AS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206695-B1 | TETRA- OR PENTA-CYCLIC LIQUID CRYSTALLINE COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-8187494-B2 | Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | KIF23, HCN3, FZD7 | FFAR4 342/4885NAAA 4128/4885TLR9 3443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.